Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.TCRT · Entity 8339 | Director | June 06, 2024 | June 10, 2024 |
| TCR2 THERAPEUTICS INC.TCRR · Entity 94327 | Chief Scientific Officer | December 09, 2021 | December 10, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date June 06, 2024 · Filed June 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2034-06-05 | Direct | 12,800 |
Reported balance
After 2024-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 12,800 · Balance 12,800 F1: One-twelfth of the Option vests each month on the monthly anniversary of June 6, 2024, with any amount that remains unvested on the date immediately preceding the Company's 2025 annual general meeting of stockholders vesting thereon. |
Filing footnotes · ownership attribution and instrument terms
F1: One-twelfth of the Option vests each month on the monthly anniversary of June 6, 2024, with any amount that remains unvested on the date immediately preceding the Company's 2025 annual general meeting of stockholders vesting thereon.
TCR2 THERAPEUTICS INC.
Report date December 09, 2021 · Filed December 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2031-12-08 | Direct | 100,000 |
Reported balance
After 2021-12-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-09 · Grant · Acquired 100,000 · Balance 100,000 F1: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. |
| Common StockSEC Table I · non-derivative | Direct | 45,850 |
Reported balance
Holding disclosure · report date 2021-12-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 45,850 |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2024 Filed Jun 10, 2024 21:00 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 12,800 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-071396 · ownership.xml · derivative · entry 1 Hofmeister Robert · CIK 0001760102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,800 Underlying: Common Stock · 12,800 shares Expires 2034-06-05 F1 · derivative.exercise_date: One-twelfth of the Option vests each month on the monthly anniversary of June 6, 2024, with any amount that remains unvested on the date immediately preceding the Company's 2025 annual general meeting of stockholders vesting thereon. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 21:24 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0000899243-23-014920 · doc4.xml · derivative · entry 1 Hofmeister Robert · CIK 0001760102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: One-twelfth of the shares underlying the option vest in equal monthly installments measured from June 6, 2023, with the first vesting occurring on July 6, 2023, subject to the Reporting Person's continued service through each such date. Read SEC document |
| March 30, 2023 Filed Apr 19, 2023 21:00 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 16,667 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0000899243-23-011453 · doc4.xml · derivative · entry 2 Hofmeister Robert · CIK 0001760102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2033-03-29 F2 · derivative.exercise_date: In equal installments on April 30, 2023 and May 30, 2023, subject to the Reporting Person's continued service through each such date. Read SEC document |
| March 30, 2023 Filed Apr 19, 2023 21:00 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0000899243-23-011453 · doc4.xml · derivative · entry 1 Hofmeister Robert · CIK 0001760102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-03-29 F1 · derivative.exercise_date: One-thirty sixth of the shares underlying the option vest in equal monthly installments measured from March 30, 2023, with the first vesting occuring on April 30, 2023, subject to the Reporting Person's continued service through each such date. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 16:30 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001209191-21-069032 · doc4.xml · derivative · entry 2 Hofmeister Robert · CIK 0001760102 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-08 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 17:26 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000899243-20-035009 · doc4.xml · derivative · entry 2 Hofmeister Robert · CIK 0001760102 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,732 Underlying: Common Stock · 7,000 shares Expires 2026-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on December 13, 2017, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 17:26 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionCommon Stock | 7,000 | $0.74 | $5,180.00 |
DisclosureSEC source: 0000899243-20-035009 · doc4.xml · nonDerivative · entry 1 Hofmeister Robert · CIK 0001760102 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 06:11 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 76,000 | $0.00 Strike: $31.83 | $0.00 |
DisclosureSEC source: 0000899243-20-033468 · doc4.xml · derivative · entry 2 Hofmeister Robert · CIK 0001760102 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 76,000 shares Expires 2030-12-09 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 16:08 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,002 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001209191-20-058274 · doc4.xml · derivative · entry 6 Hofmeister Robert · CIK 0001760102 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,730 Underlying: Common Stock · 10,002 shares Expires 2026-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: 25% of this option vested and become exercisable on December 13, 2017, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 16:08 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,998 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001209191-20-058274 · doc4.xml · derivative · entry 5 Hofmeister Robert · CIK 0001760102 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,348 Underlying: Common Stock · 9,998 shares Expires 2027-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: 25% of this option vested and become exercisable on December 7, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 16:08 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 10,002 | $25.10 | $251,050.20 |
DisclosureSEC source: 0001209191-20-058274 · doc4.xml · nonDerivative · entry 4 Hofmeister Robert · CIK 0001760102 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,850 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 16:08 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionCommon Stock | 10,002 | $0.74 | $7,401.48 |
DisclosureSEC source: 0001209191-20-058274 · doc4.xml · nonDerivative · entry 3 Hofmeister Robert · CIK 0001760102 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 16:08 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 9,998 | $25.10 | $250,949.80 |
DisclosureSEC source: 0001209191-20-058274 · doc4.xml · nonDerivative · entry 2 Hofmeister Robert · CIK 0001760102 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,850 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 16:08 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionCommon Stock | 9,998 | $0.74 | $7,398.52 |
DisclosureSEC source: 0001209191-20-058274 · doc4.xml · nonDerivative · entry 1 Hofmeister Robert · CIK 0001760102 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 14:00 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001209191-20-056390 · doc4.xml · derivative · entry 3 Hofmeister Robert · CIK 0001760102 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,346 Underlying: Common Stock · 20,000 shares Expires 2027-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on by the reporting person. F2 · derivative.exercise_date: 25% of this option vested and become exercisable on December 7, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 14:00 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 20,000 | $19.10 | $382,000.00 |
DisclosureSEC source: 0001209191-20-056390 · doc4.xml · nonDerivative · entry 2 Hofmeister Robert · CIK 0001760102 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,850 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on by the reporting person. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 14:00 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionCommon Stock | 20,000 | $0.74 | $14,800.00 |
DisclosureSEC source: 0001209191-20-056390 · doc4.xml · nonDerivative · entry 1 Hofmeister Robert · CIK 0001760102 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on by the reporting person. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 19:23 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $16.10 | $0.00 |
DisclosureSEC source: 0000899243-19-029838 · doc4.xml · derivative · entry 2 Hofmeister Robert · CIK 0001760102 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-12-18 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2021, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 16:06 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 127,512 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0001750019-19-000021 · wf-form4_155509955568771.xml · derivative · entry 1 Hofmeister Robert · CIK 0001760102 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,512 Underlying: Common Stock · 127,512 shares Expires 2029-04-10 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.